{"id":133746,"date":"2022-01-08T02:22:23","date_gmt":"2022-01-08T10:22:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/01\/goldman-sachs-asks-in-biotech-research-report-is-curing-patients-a-sustainable-business-model"},"modified":"2022-01-08T02:22:23","modified_gmt":"2022-01-08T10:22:23","slug":"goldman-sachs-asks-in-biotech-research-report-is-curing-patients-a-sustainable-business-model","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/01\/goldman-sachs-asks-in-biotech-research-report-is-curing-patients-a-sustainable-business-model","title":{"rendered":"Goldman Sachs asks in biotech research report: \u2018Is curing patients a sustainable business model?\u2019"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/goldman-sachs-asks-in-biotech-research-report-is-curing-patients-a-sustainable-business-model2.jpg\"><\/a><\/p>\n<p>\u201cThe potential to deliver \u2018one shot cures\u2019 is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,\u201d analyst Salveen Richter wrote in the note to clients Tuesday. \u201cWhile this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.\u201d<\/p>\n<p>\ud83e\udd14<\/p>\n<hr>\n<p>Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cThe potential to deliver \u2018one shot cures\u2019 is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,\u201d analyst Salveen Richter wrote in the note to clients Tuesday. \u201cWhile this proposition carries tremendous value [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,43,412],"tags":[],"class_list":["post-133746","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-business","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/133746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=133746"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/133746\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=133746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=133746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=133746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}